Conversely, TP53 mutations conferred a clonal advantage of CLL cells with a monoallelic del(11q) background, being able to outgrow cells with single del(11q) in in vivo clonal competition experiments. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.